UK Medtech Industry Points The Signpost At Better Adoption of Innovation

 
• By Ashley Yeo
  
Generate a summary of this article
Listen to this article
Beta

Often seen as complicated to access, beset with high entry barriers and with no guarantee of product adoption, the UK NHS is at once a lucrative and tricky market to succeed in for medtech innovators. A new MedTech Landscape Review, from the AHSN Network, has taken on the tasks of signposting and explaining the system, its adoption pathways and its various tools and programs, in an effort to point the way for manufacturers who want to access the NHS.

NHS

“What we’re doing here is putting a lot of detail on the innovation pathway in one place. People say this hasn’t always been the case.” So said Piers Ricketts, vice-chairman of the Academic Health Science Network (AHSN), which comprises 15 health-care product innovation organizations spread around England. The AHSNs were relicensed in 2018 with a budget of £45 million ($59m) annually, and reenergized after being included in the recent NHS Long Term Plan (LTP). (Also see "NHS' New Plan: 'Long-Termism' Is Also Needed In Adoption And Spread Of Technology In UK" - Medtech Insight, 8 January, 2019.)

Some of that new energy is being used as an opportunity to clarify, explain and simplify the concept-to-adoption pathway for...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from United Kingdom

Global Medtech Guidance Tracker: September 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Over 40 documents have been posted on the tracker since its last update.

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Global Medtech Guidance Tracker: August 2024

 
• By Vibha Sharma

Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Nearly 80 documents have been posted on the tracker since its last update.

More from Europe

Biocomposites Fully Acquires SYNICEM And Subiton Lines, Launches NanoBone In UK

 
• By Natasha Barrow

UK-based Biocomposites will begin selling in the UK its next-generation osteoinductive bone graft substitute, NanoBone, which came with its acquisition of Artoss GmbH in June 2023. Meanwhile, the company has purchased remaining shares in the manufacturers of SYNICEM and Subiton antibiotic bone cements and preformed antibiotic-loaded spacers.

Abbott’s Share-Gobbling Aveir DR Leadless Pacing System Introduced To UK

 
• By Natasha Barrow

The firm’s dual-chamber leadless pacemaker system with is expected to be a growth driver for Abbott and already has acquired approximately 30%-40% of market share from Medtronic since its approval by the US FDA in July 2023, according to GlobalData.

Amferia Aims To Bring Peptide Hydrogel To Fight Against Antimicrobial Resistance

 
• By Natasha Barrow

Amferia is developing an antimicrobial peptide hydrogel dressing to combat infections in acute wounds in humans and veterinary contexts. Supported by €1.2m of new venture capital financing, the company is planning pivotal clinical studies to support an FDA application later this year and CE mark submission in 2026-2027.